Details

Autor(en) / Beteiligte

• Mori, Yoshiko
• Ishida, Hideyuki
• Chika, Noriyasu
• Ito, Tetsuya
• Amano, Kunihiko
• Chikatani, Kenichi
• Takeuchi, Yoji
• Kono, Mitsuhiro
• Shichijo, Satoki
• Chino, Akiko
• Nagasaki, Toshiya
• Takao, Akinari
• Takao, Misato
• Nakamori, Sakiko
• Sasaki, Kazuhito
• Akagi, Kiwamu
• Yamaguchi, Tatsuro
• Tanakaya, Kohji
• Naohiro, Tomita
• Ajioka, Yoichi

Titel

Usefulness of genotyping APC gene for individualizing management of patients with familial adenomatous polyposis

Ist Teil von

• International journal of clinical oncology, 2023-12, Vol.28 (12), p.1641-1650

Ort / Verlag

Singapore: Springer Nature Singapore

Erscheinungsjahr

2023

Quelle

Alma/SFX Local Collection

Beschreibungen/Notizen

• Background Colorectal polyp burden is crucial for the management of patients with familial adenomatous polyposis (FAP). However, accurate evaluation of polyp burden is difficult to standardize. This study aimed to examine the possible utility of genotype-oriented management of colorectal neoplasms in patients with FAP. Methods Clinicopathological data from genetically proven patients with FAP was analyzed using the database of a nationwide retrospective Japanese multicenter study. The cumulative incidence of CRC was evaluated between different genotype groups. Genotype-1 were defined as germline variants on attenuated FAP-associated regions (codons 1–177, alternative splice site of exon 10 (codon 312), 1581–2843) and Genotype-2 as the other variants. Weibull and Joinpoint analyses were performed to determine the annual percentage changes in CRC risk. Results Overall, 69 men and 102 women were included. Forty-eight patients underwent colorectal resection for the first CRC, and five patients underwent resection for first cancer in the remnant anorectal segment after prophylactic surgery. The 70-year cumulative incidence of CRC in all patients was 59.3%. Patients with Genotype-1 ( n  = 23) demonstrated a lower risk of CRC stages II–IV than those with Genotype-2 ( n  = 148, P  = 0.04). The risk of stage II–IV CRC was estimated to increase markedly at the age of 49 years in the Genotype-1 patients and 34 years in the Genotype-2 patients, respectively. Conclusions Different interventional strategies based on genotypes may be proposed for the clinical management of patients with FAP. This policy needs to be validated in further prospective studies focusing on long-term endoscopic intervention and optimal age at prophylactic (procto)colectomy.